BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 9707435)

  • 1. A role for helix 3 of the TRbeta ligand-binding domain in coactivator recruitment identified by characterization of a third cluster of mutations in resistance to thyroid hormone.
    Collingwood TN; Wagner R; Matthews CH; Clifton-Bligh RJ; Gurnell M; Rajanayagam O; Agostini M; Fletterick RJ; Beck-Peccoz P; Reinhardt W; Binder G; Ranke MB; Hermus A; Hesch RD; Lazarus J; Newrick P; Parfitt V; Raggatt P; de Zegher F; Chatterjee VK
    EMBO J; 1998 Aug; 17(16):4760-70. PubMed ID: 9707435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of the functional role of steroid receptor coactivator-1 in ligand-induced transactivation by thyroid hormone receptor.
    Jeyakumar M; Tanen MR; Bagchi MK
    Mol Endocrinol; 1997 Jun; 11(6):755-67. PubMed ID: 9171239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel natural mutation in the thyroid hormone receptor defines a dual functional domain that exchanges nuclear receptor corepressors and coactivators.
    Tagami T; Gu WX; Peairs PT; West BL; Jameson JL
    Mol Endocrinol; 1998 Dec; 12(12):1888-902. PubMed ID: 9849963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defective release of corepressor by hinge mutants of the thyroid hormone receptor found in patients with resistance to thyroid hormone.
    Safer JD; Cohen RN; Hollenberg AN; Wondisford FE
    J Biol Chem; 1998 Nov; 273(46):30175-82. PubMed ID: 9804773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance to thyroid hormone caused by two mutant thyroid hormone receptors beta, R243Q and R243W, with marked impairment of function that cannot be explained by altered in vitro 3,5,3'-triiodothyroinine binding affinity.
    Yagi H; Pohlenz J; Hayashi Y; Sakurai A; Refetoff S
    J Clin Endocrinol Metab; 1997 May; 82(5):1608-14. PubMed ID: 9141558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spectrum of transcriptional, dimerization, and dominant negative properties of twenty different mutant thyroid hormone beta-receptors in thyroid hormone resistance syndrome.
    Collingwood TN; Adams M; Tone Y; Chatterjee VK
    Mol Endocrinol; 1994 Sep; 8(9):1262-77. PubMed ID: 7838159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathological Interactions Between Mutant Thyroid Hormone Receptors and Corepressors and Their Modulation by a Thyroid Hormone Analogue with Therapeutic Potential.
    Harrus D; Déméné H; Vasquez E; Boulahtouf A; Germain P; Figueira AC; Privalsky ML; Bourguet W; le Maire A
    Thyroid; 2018 Dec; 28(12):1708-1722. PubMed ID: 30235988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A de novo mutation in an already mutant nucleotide of the thyroid hormone receptor beta gene perpetuates resistance to thyroid hormone.
    Lado-Abeal J; Dumitrescu AM; Liao XH; Cohen RN; Pohlenz J; Weiss RE; Lebrethon MC; Verloes A; Refetoff S
    J Clin Endocrinol Metab; 2005 Mar; 90(3):1760-7. PubMed ID: 15598685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel TR beta mutation (R383H) in resistance to thyroid hormone syndrome predominantly impairs corepressor release and negative transcriptional regulation.
    Clifton-Bligh RJ; de Zegher F; Wagner RL; Collingwood TN; Francois I; Van Helvoirt M; Fletterick RJ; Chatterjee VK
    Mol Endocrinol; 1998 May; 12(5):609-21. PubMed ID: 9605924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative analysis of DNA binding affinity and dimerization properties of wild-type and mutant thyroid hormone receptor beta1.
    Takeda T; Nagasawa T; Miyamoto T; Minemura K; Hashizume K; Degroot LJ
    Thyroid; 2000 Jan; 10(1):11-8. PubMed ID: 10691308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nuclear corepressors enhance the dominant negative activity of mutant receptors that cause resistance to thyroid hormone.
    Tagami T; Jameson JL
    Endocrinology; 1998 Feb; 139(2):640-50. PubMed ID: 9449636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcriptional activation by thyroid hormone receptor-beta involves chromatin remodeling, histone acetylation, and synergistic stimulation by p300 and steroid receptor coactivators.
    Lee KC; Li J; Cole PA; Wong J; Kraus WL
    Mol Endocrinol; 2003 May; 17(5):908-22. PubMed ID: 12586842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A natural transactivation mutation in the thyroid hormone beta receptor: impaired interaction with putative transcriptional mediators.
    Collingwood TN; Rajanayagam O; Adams M; Wagner R; Cavaillès V; Kalkhoven E; Matthews C; Nystrom E; Stenlof K; Lindstedt G; Tisell L; Fletterick RJ; Parker MG; Chatterjee VK
    Proc Natl Acad Sci U S A; 1997 Jan; 94(1):248-53. PubMed ID: 8990194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thyroid hormone resistance syndrome manifests as an aberrant interaction between mutant T3 receptors and transcriptional corepressors.
    Yoh SM; Chatterjee VK; Privalsky ML
    Mol Endocrinol; 1997 Apr; 11(4):470-80. PubMed ID: 9092799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of coactivator interaction can be a mechanism for dominant negative activity by mutant thyroid hormone receptors.
    Liu Y; Takeshita A; Misiti S; Chin WW; Yen PM
    Endocrinology; 1998 Oct; 139(10):4197-204. PubMed ID: 9751500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Requirement of corepressor binding of thyroid hormone receptor mutants for dominant negative inhibition.
    Nagaya T; Fujieda M; Seo H
    Biochem Biophys Res Commun; 1998 Jun; 247(3):620-3. PubMed ID: 9647743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel resistance to thyroid hormone associated with a new mutation (T329N) in the thyroid hormone receptor beta gene.
    Sarkissian G; Dace A; Mesmacque A; Bony-Trifunovic H; Malezet-Desmoulins C; Torresani J; Margotat A
    Thyroid; 1999 Feb; 9(2):165-71. PubMed ID: 10090317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thyroid hormone receptor-beta mutations conferring hormone resistance and reduced corepressor release exhibit decreased stability in the N-terminal ligand-binding domain.
    Huber BR; Desclozeaux M; West BL; Cunha-Lima ST; Nguyen HT; Baxter JD; Ingraham HA; Fletterick RJ
    Mol Endocrinol; 2003 Jan; 17(1):107-16. PubMed ID: 12511610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel thyroid hormone receptor-beta mutation that fails to bind nuclear receptor corepressor in a patient as an apparent cause of severe, predominantly pituitary resistance to thyroid hormone.
    Wu SY; Cohen RN; Simsek E; Senses DA; Yar NE; Grasberger H; Noel J; Refetoff S; Weiss RE
    J Clin Endocrinol Metab; 2006 May; 91(5):1887-95. PubMed ID: 16464943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel mutation (E333D) in the thyroid hormone beta receptor causing resistance to thyroid hormone syndrome.
    Maraninchi M; Bourcigaux N; Dace A; El-Yazidi C; Malezet-Desmoulins C; Krempf M; Torresani J; Margotat A
    Exp Clin Endocrinol Diabetes; 2006 Nov; 114(10):569-76. PubMed ID: 17177139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.